GL-ONC1
GL-ONC1 is an oncolytic virus that is currently being studied for its potential use in the treatment of various types of cancer. It is a genetically modified vaccinia virus that is designed to selectively replicate in cancer cells, causing them to lyse and die.
Mechanism of Action[edit | edit source]
GL-ONC1 works by exploiting the unique characteristics of cancer cells. Unlike normal cells, cancer cells have a compromised immune system, which allows the virus to infect and replicate within them without being detected and destroyed. Once inside the cancer cells, the virus causes them to burst, releasing more viruses that can then infect other cancer cells. This cycle continues until all the cancer cells are destroyed.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the safety and efficacy of GL-ONC1. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates. However, more research is needed to fully understand the potential benefits and risks of this treatment.
Potential Applications[edit | edit source]
GL-ONC1 has the potential to be used in the treatment of a wide range of cancers, including ovarian cancer, mesothelioma, head and neck cancer, and non-small cell lung cancer. It may also be used in combination with other treatments, such as chemotherapy and radiation therapy, to enhance their effectiveness.
Side Effects[edit | edit source]
As with any treatment, GL-ONC1 has the potential to cause side effects. These may include flu-like symptoms, such as fever and fatigue, as well as more serious complications, such as infection and organ damage. However, these side effects are generally manageable and are often outweighed by the potential benefits of the treatment.
Future Research[edit | edit source]
Future research on GL-ONC1 will focus on optimizing its delivery to cancer cells, improving its safety profile, and exploring its potential use in combination with other treatments. This research will be crucial in determining the full potential of this promising new treatment.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
